MVPA Mortality Risk Reduction Not Tied to Exercise in Bouts

Share this content:
MVPA Mortality Risk Reduction Not Tied to Exercise in Bouts
MVPA Mortality Risk Reduction Not Tied to Exercise in Bouts

FRIDAY, March 23, 2018 (HealthDay News) -- Moderate-to-vigorous physical activity (MVPA) is associated with reduced mortality risk, regardless of whether it is accumulated in bouts, according to a study published online March 22 in the Journal of the American Heart Association.

Pedro F. Saint-Maurice, Ph.D., from the National Cancer Institute in Bethesda, Md., and colleagues analyzed data from the 2003 to 2006 National Health and Nutrition Examination Survey (NHANES) and death records available through 2011 to examine the correlations between objectively measured physical activity accumulated with and without bout criteria and all-cause mortality. Data were included for 4,840 adults aged 40 and older. Physical activity data were processed to generate minutes/day of total and bouted MVPA, with bouted MVPA defined as MVPA accumulated in bouts of a minimum duration of five or 10 minutes.

The researchers found that there were similar hazard ratios for all-cause mortality associated with total and bouted MVPA, ranging from 0.24 for the third quartile of total MVPA to 0.44 for the second quartile of 10-minute bouts. Greater amounts of bouted MVPA did not result in additional risk reductions for mortality.

"These results provide evidence that mortality risk reductions associated with MVPA are independent of how activity is accumulated and can impact the development of physical activity guidelines and inform clinical practice," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Disease-carrying ticks were detected in 83 counties where they'd never been found before

Availability of Generic Antivirals for Hepatitis B Increasing

Availability of Generic Antivirals for Hepatitis B Increasing

Drop in median price of WHO-prequalified generic tenofovir from $208 to $32 from 2004 to 2016

Visual Function Deficits Up in Developmental Dyslexia

Visual Function Deficits Up in Developmental Dyslexia

Increased prevalence of deficits in visual function versus typically developing school-age children

is free, fast, and customized just for you!




Already a member?

Sign In Now »